Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer.
Animals
Breast Neoplasms
/ metabolism
Cell Differentiation
Cell Line, Tumor
Cell Proliferation
/ physiology
Cell Self Renewal
/ physiology
Epithelial Cells
/ metabolism
Female
Humans
Mammary Glands, Animal
/ abnormalities
Mesenchymal Stem Cells
/ metabolism
Mice
Mice, Knockout
MicroRNAs
/ genetics
Neoplastic Stem Cells
/ metabolism
RNA, Neoplasm
/ physiology
Spheroids, Cellular
Triple Negative Breast Neoplasms
/ metabolism
Wnt Signaling Pathway
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
20
11
2017
accepted:
19
06
2018
revised:
06
06
2018
pubmed:
11
8
2018
medline:
23
4
2019
entrez:
11
8
2018
Statut:
ppublish
Résumé
The role of the tumour-suppressor miR-34 family in breast physiology and in mammary stem cells (MaSCs) is largely unknown. Here, we revealed that miR-34 family, and miR-34a in particular, is implicated in mammary epithelium homoeostasis. Expression of miR-34a occurs upon luminal commitment and differentiation and serves to inhibit the expansion of the pool of MaSCs and early progenitor cells, likely in a p53-independent fashion. Mutant mice (miR34-KO) and loss-of-function approaches revealed two separate functions of miR-34a, controlling both proliferation and fate commitment in mammary progenitors by modulating several pathways involved in epithelial cell plasticity and luminal-to-basal conversion. In particular, miR-34a acts as endogenous inhibitor of the Wnt/beta-catenin signalling pathway, targeting up to nine upstream regulators at the same time, thus modulating the expansion of the MaSCs/early progenitor pool. These multiple roles of miR-34a are maintained in a model of human breast cancer, in which chronic expression of miR-34a in triple-negative mesenchymal-like cells (enriched in cancer stem cells-CSCs) could promote a luminal-like differentiation programme, restrict the CSC pool, and inhibit tumour propagation. Hence, activation of miR-34a-dependent programmes could provide a therapeutic opportunity for the subset of breast cancers, which are rich in CSCs and respond poorly to conventional therapies.
Identifiants
pubmed: 30093634
doi: 10.1038/s41388-018-0445-3
pii: 10.1038/s41388-018-0445-3
pmc: PMC6336680
doi:
Substances chimiques
MIRN34 microRNA, human
0
MIRN34a microRNA, mouse
0
MicroRNAs
0
RNA, Neoplasm
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
360-374Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA149707
Pays : United States
Organisme : Fondazione Cariplo (Cariplo Foundation)
ID : 2015-0590
Pays : International
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG18774
Pays : International
Commentaires et corrections
Type : ErratumIn
Références
Oncogene. 2000 Feb 21;19(8):1002-9
pubmed: 10713683
Genes Dev. 2000 Mar 15;14(6):650-4
pubmed: 10733525
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nature. 2006 Feb 23;439(7079):993-7
pubmed: 16395311
Nature. 2006 Jan 5;439(7072):84-8
pubmed: 16397499
Dev Biol. 2006 May 15;293(2):414-25
pubmed: 16545360
J Biol Chem. 2006 Nov 17;281(46):35081-7
pubmed: 16973609
Nat Cell Biol. 2006 Dec;8(12):1398-406
pubmed: 17072303
Cancer Cell. 2007 Mar;11(3):259-73
pubmed: 17349583
Nature. 2007 Jun 28;447(7148):1130-4
pubmed: 17554337
Nat Biotechnol. 2007 Dec;25(12):1457-67
pubmed: 18026085
Cell. 2007 Dec 14;131(6):1109-23
pubmed: 18083101
Breast Cancer Res. 2008;10(2):R25
pubmed: 18366788
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Nat Rev Mol Cell Biol. 2008 May;9(5):355-66
pubmed: 18431399
Cell Cycle. 2008 Aug 15;7(16):2591-600
pubmed: 18719384
Cancer Res. 2008 Dec 15;68(24):10094-104
pubmed: 19074875
Nat Rev Mol Cell Biol. 2009 Feb;10(2):116-25
pubmed: 19165214
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3207-12
pubmed: 19202062
Cell. 2009 Aug 7;138(3):592-603
pubmed: 19665978
Cell. 2009 Sep 18;138(6):1083-95
pubmed: 19766563
Cell. 2010 Jan 8;140(1):62-73
pubmed: 20074520
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6334-9
pubmed: 20308559
Breast Cancer Res. 2010;12(2):R21
pubmed: 20346151
J Clin Oncol. 2010 Sep 1;28(25):4006-12
pubmed: 20498387
Nat Med. 2011 Feb;17(2):211-5
pubmed: 21240262
Nat Cell Biol. 2011 Mar;13(3):317-23
pubmed: 21336307
PLoS One. 2011;6(8):e21396
pubmed: 21857907
Nat Cell Biol. 2011 Oct 23;13(11):1353-60
pubmed: 22020437
Sci Signal. 2011 Nov 01;4(197):ra71
pubmed: 22045851
Nature. 2012 Feb 15;482(7385):347-55
pubmed: 22337054
Cell. 2012 Mar 2;148(5):1015-28
pubmed: 22385965
Front Genet. 2012 Jul 02;3:120
pubmed: 22783274
PLoS Genet. 2012;8(7):e1002797
pubmed: 22844244
Cell Stem Cell. 2012 Sep 7;11(3):387-400
pubmed: 22863533
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Cell Biol. 2012 Oct 1;199(1):77-95
pubmed: 23027903
Nature. 2013 Mar 7;495(7439):107-10
pubmed: 23426265
Cell Stem Cell. 2013 May 2;12(5):602-15
pubmed: 23642368
Sci Rep. 2013;3:2687
pubmed: 24045437
J Mol Cell Biol. 2014 Jun;6(3):214-30
pubmed: 24815299
Nature. 2014 Jun 5;510(7503):115-20
pubmed: 24899310
Nature. 2014 Aug 28;512(7515):431-5
pubmed: 25043055
Cancer Res. 2014 Dec 15;74(24):7573-82
pubmed: 25368020
Cancer Sci. 2015 Jun;106(6):700-8
pubmed: 25783790
Tumour Biol. 2017 May;39(5):1010428317701652
pubmed: 28468587
Cell. 1982 Nov;31(1):99-109
pubmed: 6297757